|
Since February 2006, Dr. Azab, QLT IncÂ’s former Chief Medical Officer and Executive Vice President of Research and Development, has been a member of our board of directors. During his tenure with QLT Inc, Dr. Azab was responsible for preclinical research and development, regulatory affairs, quality assurance, clinical research, medical affairs, pharmaceutical development, and device engineering. Since joining QLT in 1997, he engineered the growth of the development functions at QLT to be a core competency for the company that delivered 5 different NDA submissions for 2 products (PHOTOFRIN and VISUDYNE).
Dr. Azab is currently President & CEO of Intradigm Corporation, a privately owned US biotechnology drug development company. He brings more than 20 years of experience in clinical research and the pharmaceutical industry, including medical management for Sanofi (Sanofi-Avantis) Pharmaceuticals' oncology program working in France and leadership of the clinical drug development in oncology at Zeneca (Astra-Zeneca) Pharmaceuticals in the company's R&D headquarters in England. During his career, he managed drug development programs that led to the approval and marketing of seven different new chemical entities in the therapeutic areas of oncology, gastroenterology, urology, and ophthalmology.
Dr. Azab received his medical degree from Cairo University in 1979. He practiced as a medical oncologist and received post-graduate training and degrees from the University of Paris-Sud and the University of Pierre and Marie Curie in France. He has authored more than 100 medical papers and abstracts and is an active member of the American Society of Clinical Oncology, the American Association of Cancer Research, and the European Society of Medical Oncology. Dr. Azab also holds an MBA degree with distinction from the Richard Ivey School of Business, University of Western Ontario. | 